Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 50 of 106 publications.
Skip to main content
Law EH, Hanson KA, Harries M, Korver D, Sherif B, Chirila C. Patient-reported outcome improvements following scalp hair regrowth among patients with alopecia areata: analysis of the ALLEGRO-2b/3 trial. J Dermatolog Trea. 2025 Feb 3;36(1):2460577. doi: 10.1080/09546634.2025.2460577
Law EH, Sherif B, Mostaghimi A, King B, Sinclair R, Mesinkovshka N, Hanson KA, Korver D, Chirila C. Patients with alopecia areata treated with ritlecitinib have improved patient-reported emotional symptoms and activity limitations due to hair loss: post hoc analyses of ALLEGRO-2b/3. Poster presented at the Maui Derm Hawaii 2024; January 22, 2024. Wailea, HI.
Sherif B, Burke M, Besse B, Solomon B, Bazhenova L, Kim DW, Lin JJ, Wolf J, Popat S, Goto K, de Langen AJ, Springfeld C, Reynolds M, Odom D, Yuan Y, Lee A, Blum SI, Thamake S, Ades F, Drilon A. Health-related quality-of-life of patients treated with repotrectinib for neurotrophic tyrosine receptor kinase (NTRK)-positive advanced solid tumors: results From TRIDENT-1. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S484. doi: 10.1016/j.jval.2023.09.2619
Sinclair G, Sension M, Dretler A, Schneider S, Schubert C, Merrill D, Richardson D, Sherif B, Zografos L, Garris C. Clinical outcomes at month 6 after initiation of cabotegravir and rilpivirine long-acting (CAB+RPV LA) in an observational real-world study (BEYOND). Poster presented at the IDWeek 2023; October 13, 2023. Boston, MA.
Wolf J, Garon EB, Groen HJM, Tan DSW, Gilloteau I, Le Mouhaer S, Hampe M, Cai C, Chassot-Agostinho C, Reynolds M, Sherif B, Heist RS. Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: results from the GEOMETRY mono-1 study. Eur J Cancer. 2023 Apr;183:98-108. doi: 10.1016/j.ejca.2022.10.030
Taylor MH, Leboulleux S, Panaseykin Y, Konda B, de La Fouchardiere C, Hughes BGM, Gianoukakis AG, Park YJ, Romanov I, Krzyzanowska MK, Garbinsky D, Sherif B, Pan JJ, Binder TA, Sauter N, Xie R, Brose MS. Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day. Cancer Med. 2023 Feb;12(4):4332-42. doi: 10.1002/cam4.5308
Shim A, Trone D, Reynolds M, Odom D, Sherif B, Stopatschinskaja S. Patient reported outcomes (PRO) from phase 2 registrational trial of repotrectinib in patients with ROS1-positive advanced or metastatic non-small cell lung cancer (TRIDENT-1). Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S421. doi: 10.1016/j.jval.2022.09.2093
Law EH, Sherif B, Williams NJ, Mitra D, Neary MP, Nelson LM, Harries M. Improvements in patient-reported outcomes based on scalp hair regrowth among patients with alopecia areata: analysis of the allegro 2b/3 trial. Poster presented at the 31st EADV Congress; September 7, 2022. Milan, Italy.
Spira A, Liao L, Zhou X, Sherif B, Chen L, Ungar D, Yu E, Radford J, Hamadani M. Health-related quality of life, symptoms, and tolerability of Loncastuximab Tesirine in older versus younger patients with relapsed/refractory diffuse large b-cell lymphoma treated in a phase 2 clinical trial (LOTIS-2). Poster presented at the National Comprehensive Cancer Network (NCCN) 2022 Virtual Annual Conference; March 31, 2022.
Strand V, Kaeley GS, Bergman MJ, Gladman DD, Coates LC, Sherif B, Hur P, Parikh B, Gilloteau I, Mease PJ. The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomized phase 3 trial. Lancet Rheumatol. 2022 Mar 1;4(3):e208-19.
Baraliakos X, Van den Bosch F, Machado PM, Gensler LS, Marzo-Ortega H, Sherif B, Quebe-Fehling E, Porter B, Gaillez C, Deodhar A. Achievement of remission endpoints with secukinumab over 3 years in active ankylosing spondylitis: pooled analysis of two phase 3 studies. Rheum Ther. 2021 Mar;8(1):273-88. doi: 10.1007/s40744-020-00269-6
Taylor MH, Leboulleux S, Panaseykin S, Konda B, de La Fouchardiere C, Hughes BGM, Gianoukakis AG, Park YJ, Romanov I, Krzyzanowska MK, Garbinsky D, Sherif B, Pan JJ, Binder TA, Sauter N, Xie R, Brose MS. Health-related quality-of-life (HRQoL) analyses from study 211: a phase 2 study in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) treated with 2 starting doses of lenvatinib (LEN). Poster presented at the 46th Congress of European Society for Medical Oncology (ESMO); September 16, 2021. [abstract] Ann Oncol. 2021; 32(suppl_5):S1205-10. doi: 10.1016/annonc/annonc715
Himmler S, Mueller M, Sherif B, Ostwald D. A case study applying a novel approach to estimate the social impact of a medical innovation - the use of secukinumab for psoriatic arthritis in Germany. Expert Rev Pharmacoecon Outcomes Res. 2019 Jul 29. doi: 10.1080/14737167.2019.1644169
Kooli A, Graham C, Scheuer N, Gilloteau I, Miles L, Sherif B, McBride D. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared to ustekinumab and etanercept in Morocco. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.
Kooli A, Graham C, Scheuer N, Gilloteau I, Miles L, Sherif B, McBride D. Secukinumab significantly reduces psoriasis-related work impairment and indirect costs compared to ustekinumab and etanercept in Tunisia. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.
Coates L, Gossec L, Kirkham B, Sherif B, Gaillez C, Mpofu S, Jugl SM, Karyekar C, Gandhi KK. Minimal disease activity among active psoriatic arthritis patients treated with Secukinumab: 2-year results from a multicenter, randomized, double-blind, parallel-group, placebo-controlled phase III study. Arthritis Care Res (Hoboken). 2018 Oct;70(10):1529-35. doi: 10.1002/acr.23537
Stull DE, Griffiths CEM, Gilloteau I, Zhao Y, Guana A, Finlay AY, Sherif B, Houghton K, Puig L. Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis. Br J Dermatol. 2018 Jun;178(6):1297-307. doi: 10.1111/bjd.16366
Odom D, McLeod L, Sherif B, Nelson L, McSorley D. Longitudinal modeling approaches to assess the association between changes in 2 clinical outcome assessments. Ther Innov Regul Sci. 2018 May;52(3):306-12. doi: 10.1177/2168479017731584
Warren R, Halliday A, Graham CN, Gilloteau I, Miles L, Sherif B, McBride D. Secukinumab significantly reduces work impairment and indirect costs compared to ustekinumab and etanercept in the United Kingdom. Poster presented at the 2017 ISPOR 20th Annual European Congress; November 8, 2017. Glasgow, Scotland.
Elewski BE, Puig L, Mordin M, Gilloteau I, Sherif B, Fox T, Gnanasakthy A, Papavassilis C, Strober BE. Psoriasis patients with Psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. J Dermatolog Trea. 2017 Sep;28(6):492-9. doi: 10.1080/09546634.2017.1307464
Sherif B, Graham CN, Neidhardt K, Gilloteau I, O'Neill CB, McBride D, Augustin M. EQ-5D-3L utilities tariffs: differences in German and UK utilities and QALYS in patients with moderate to severe psoriasis. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A331.
Marzo-Ortega H, Halliday A, Jugl S, Mokashi S, Porter B, Talloczy Z, Sherif B, Williams N, Keat A. Impact of alternative definitions of treatment response on long-term efficacy of secukinumab in tumour necrosis factor alpha-naïve patients with active ankylosing spondylitis. Poster presented at the British Society for Rheumatology 2017; April 25, 2017. Birmingham, United Kingdom.
Emery P, Halliday A, Jugl S, Mokashi S, Porter B, Martin R, Sherif B, Williams N, Marzo-Ortega H. Week 12 response predicts long-term efficacy of secukinumab in patients with active ankylosing spondylitis independent of previous TNFi exposure. Poster presented at the British Society for Rheumatology 2017; April 2017. Birmingham, United Kingdom.
Strober B, Gottlieb AB, Sherif B, Mollon P, Gilloteau I, McLeod L, Fox T, Mordin M, Gnanasakthy A, Papavassilis C, Lebwohl MG. Secukinumab sustains early patient-reported outcome benefits through 1 year: results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. J Am Acad Dermatol. 2017 Apr;76(4):655-61. doi: 10.1016/j.jaad.2016.11.043
Strober B, Blauvelt A, Zhao Y, Milutinovic M, Mollon P, You R, Sherif B, Williams N, Fox T, Augustin M, Lebwohl M. Secukinumab provides better relief from psoriasis-related pain, itching, and scaling than ustekinumab. Poster presented at the 17th Annual Las Vegas Dermatology Seminar & the 13th Annual Psoriasis Forum; November 12, 2016. Las Vegas, NV.
Tyring S, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Sherif B, Williams N, Nyirady J, Korman N. Secukinumab provides better relief from quality-of-life impact than etanercept in moderate to severe psoriasis. Poster presented at the 17th Annual Las Vegas Dermatology Seminar & the 13th Annual Psoriasis Forum; November 12, 2016. Las Vegas, NV.
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B, McLeod L, Nyirady J, Tyring S. Secukinumab provides better relief from quality-of-life impact than placebo in moderate to severe psoriasis. Poster presented at the 17th Annual Las Vegas Dermatology Seminar & the 13th Annual Psoriasis Forum; November 12, 2016. Las Vegas, NV.
Blauvelt A, Korman N, Mollon P, Zhao Y, Milutinovic M, You R, Sherif B, Williams N, Fox T, Augustin M. Secukinumab provides faster and better quality of life impact than ustekinumab in psoriasis. Poster presented at the 17th Annual Las Vegas Dermatology Seminar & the 13th Annual Psoriasis Forum; November 10, 2016. Las Vegas, NV.
Tyring S, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Sherif B, Williams N, Nyirady J, Korman N. Secukinumab provides more effective relief from skin-related quality-of-life impact than etanercept in moderate to severe psoriasis. Poster presented at the SDPA 14th Annual Fall Dermatology Conference 2016; November 6, 2016. Las Vegas, NV. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B, McLeod L, Nyirady J, Tyring S. Secukinumab provides more effective relief from skin-related quality-of-life impact than placebo in moderate to severe psoriasis. Poster presented at the SDPA 14th Annual Fall Dermatology Conference 2016; November 6, 2016. Las Vegas, NV. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Tyring S, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Sherif B, Williams N, Nyirady J, Korman N. Secukinumab provides more effective relief from skin-related quality-of-life impact than etanercept in moderate to severe psoriasis. Poster presented at the 35th Anniversary Fall Clinical Dermatology Conference; October 23, 2016. Las Vegas, NV. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B, McLeod L, Nyirady J, Tyring S. Secukinumab provides more effective relief from skin-related quality-of-life impact than placebo in moderate to severe psoriasis. Poster presented at the 35th Anniversary Fall Clinical Dermatology Conference; October 23, 2016. Las Vegas, NV. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Strober B, Blauvelt A, Zhao Y, Milutinovic M, Mollon P, You R, Sherif B, Williams N, Fox T, Augustin M, Lebwohl M. Secukinumab treatment provides more effective relief from patient-reported psoriasis-related pain, itching, and scaling than ustekinumab. Poster presented at the 35th Anniversary Fall Clinical Dermatology Conference; October 20, 2016. Las Vegas, NV. Previously presented at the 24th European Academy of Dermatology and Venereology Congress.
Blauvelt A, Korman N, Mollon P, Zhou Y, Milutinovic M, You R, Sherif B, Williams N, Fox T, Augustin M. Secukinumab treatment provides faster and more effective relief from patient-reported quality of life impact than ustekinumab in subjects with moderate to severe plaque psoriasis. Poster presented at the 35th Anniversary Fall Clinical Dermatology Conference; October 20, 2016. Las Vegas, NV. Previously presented at the 24th European Academy of Dermatology and Venereology Congress.
Tyring S, Sofen H, Fretzin S, Rich P, Zhao Y, Herrera V, Sherif B, Williams N, Nyirady J, Korman N. Secukinumab provides more effective relief from skin-related quality-of-life impact than etanercept in moderate to severe psoriasis. Poster presented at the Maui Derm NP+ PA Fall 2016; September 29, 2016. Asheville, NC. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Sofen H, Korman N, Rich P, Fretzin S, Zhao Y, Herrera V, Sherif B, McLeod L, Nyirady J, Tyring S. Secukinumab provides more effective relief from skin-related quality-of-life impact than placebo in moderate to severe psoriasis. Poster presented at the Maui Derm NP+ PA Fall 2016; September 29, 2016. Asheville, NC. Previously presented at the American Academy of Dermatology 74th Annual Meeting.
Strober B, Jazayeri S, Thaci D, Augustin M, Zhou Y, Gilloteau I, McLeod LD, Sherif B, Herrera V, Nyirady J, Guana A, Lebwohl M. Secukinumab provides faster and more sustained 52-week complete relief from psoriasis-related pain, itching, and scaling than ustekinumab in subjects with moderate-to-severe plaque psoriasis. Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.
Vender R, Leonardi C, Puig L, Ziv M, Zhou Y, Gilloteau I, Sherif B, McLeod LD, Nyirady J, Guana A, Strober B. Secukinumab provides greater cumulative 52-week skin clearance and quality of life benefit in patients with moderate-to-severe plaque psoriasis than ustekinumab: an area under the curve analysis. Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.
Marion S, Tzivelekis S, Darden C, Price MA, Sherif B, Garcia J, Kaye JA, Chandler D. "Same-day" administration of pegfilgrastim following myelosuppressive chemotherapy: clinical practice and provider rationale. Support Care Cancer. 2016 Sep;24(9):3889-96. doi: 10.1007/s00520-016-3193-3
Augustin M, Korman N, Zhao Y, Gilloteau I, Herrera V, Sherif B, Williams N, Blauvelt A. Secukinumab skin clearance is associated with greater improvements in skin-related quality of life. Presented at the 2016 AAD Summer Meeting; July 2016. Boston, MA.